GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,711.20p
   
  • Change Today:
      6.00p
  • 52 Week High: 1,711.60
  • 52 Week Low: 1,316.00
  • Currency: UK Pounds
  • Shares Issued: 4,144.88m
  • Volume: 1,918,916
  • Market Cap: £70,927m
  • RiskGrade: 129

GSK cancer treatment meets trial endpoint

By Frank Prenesti

Date: Friday 02 Dec 2022

LONDON (ShareCast) - (Sharecast News) - GSK on Friday unveiled positive headline results from a Phase 3 trial of its Jemperli endometrial cancer drug.


The company said Jemperli met its primary endpoint of investigator-assessed progression-free survival (PFS) and showed a "statistically significant and clinically meaningful benefit".

Endometrial cancer is found in the inner lining of the uterus, known as the endometrium. It is the most common gynaecologic cancer in the US and the second most common gynaecologic cancer globally.

Approximately 15-20% of women with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis.

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,711.20p
Change Today 6.00p
% Change 0.35 %
52 Week High 1,711.60
52 Week Low 1,316.00
Volume 1,918,916
Shares Issued 4,144.88m
Market Cap £70,927m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
83.02% below the market average83.02% below the market average83.02% below the market average83.02% below the market average83.02% below the market average
51.85% below the sector average51.85% below the sector average51.85% below the sector average51.85% below the sector average51.85% below the sector average
Price Trend
49.26% above the market average49.26% above the market average49.26% above the market average49.26% above the market average49.26% above the market average
75.44% above the sector average75.44% above the sector average75.44% above the sector average75.44% above the sector average75.44% above the sector average
Income
35.10% above the market average35.10% above the market average35.10% above the market average35.10% above the market average35.10% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
27.09% below the market average27.09% below the market average27.09% below the market average27.09% below the market average27.09% below the market average
29.73% above the sector average29.73% above the sector average29.73% above the sector average29.73% above the sector average29.73% above the sector average

What The Brokers Say

Strong Buy 7
Buy 6
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 22-Feb-24 16-Nov-23
Paid 11-Apr-24 11-Jan-24
Amount 16.00p 14.00p

Trades for 28-Mar-2024

Time Volume / Share Price
15:37 1,120 @ 1,711.20p
15:37 100 @ 1,711.20p
15:37 372 @ 1,711.20p
15:37 2 @ 1,711.20p
15:37 71 @ 1,711.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page